Ibandrocare 150mg 2 Scored Film Coated Tablets

Active Ingredient: Ibandronic Acid Postmenopausal osteoporosis: Treatment and prevention of osteoporosis in postmenopausal females. Limitations of use: The optimal duration has not been determined. Safety and efficacy for osteoporosis treatment are based on clinical data of 3-years duration (oral) and 1-year duration (IV). All patients on bisphosphonate therapy should be re-evaluated periodically for the need to continue therapy. Consider discontinuing after 3 to 5 years in patients at low-risk for fracture. Re-evaluate fracture risk periodically in patients who discontinue therapy.